3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
9
Active not recruiting
6
Withdrawn
3
Unknown
3
Recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
19
Breast Neoplasms
12
Lung Neoplasms
10
Brain Neoplasms
9
Glioblastoma
7
Neoplasm Metastasis
6
Neoplasms
5
Glioma
5
Carcinoma, Renal Cell
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Pancreatic Neoplasms
4
Head and Neck Neoplasms
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Mycosis Fungoides
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Liver Neoplasms
3
Gliosarcoma
3
Waldenstrom Macroglobulinemia
2
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Sezary Syndrome
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroendocrine Tumors
2
Interventions
Temozolomide
11
Radiotherapy
11
Filgrastim
6
Granulocyte Colony-Stimulating Factor
4
Chemotherapy, Adjuvant
4
etoposide phosphate
3
Topotecan
3
O(6)-benzylguanine
3
Melphalan
3
Etoposide
3
Cyclophosphamide
3
Carboplatin
3
sodium thiosulfate
2
sargramostim
2
Thiotepa
2
Radiotherapy, Intensity-Modulated
2
Methylphenidate
2
Mannitol
2
Ifosfamide
2
Carmustine
2
Busulfan
2
Bone Marrow Transplantation
2
Bevacizumab
2
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
temsirolimus
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
poly ICLC
1
pentetreotide
1
pemigatinib
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Central Nervous System Neoplasms
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT00633958
2021-10-20
FLT
Dana-Farber Cancer Institute
Phase 1
Terminated
2 enrolled